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BACKGROUND: Recent trials have identified anti–diabetes mellitus agents that lower major adverse cardiovascular event 
(MACE) rates, although some increase rates of lower-extremity amputation (LEA). Patients with peripheral artery disease 
(PAD) have greater incidence of diabetes mellitus and risk for LEA, prompting this investigation of clinical outcomes in 
patients with diabetes mellitus and PAD in the EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering).
METHODS: EXSCEL evaluated the effects of once-weekly exenatide (a GLP-1 [glucagon-like peptide-1] receptor agonist) 
versus placebo on the rates of the primary composite MACE end point (cardiovascular death, myocardial infarction, or stroke) 
among patients with type 2 diabetes mellitus. In this post hoc analysis, we assessed the association of baseline PAD with 
rates of MACE, LEA, and the effects of exenatide versus placebo in patients with and without PAD.
RESULTS: EXSCEL included 2800 patients with PAD (19% of the trial population). These individuals had higher unadjusted 
and adjusted rates of MACE compared with patients without PAD (13.6% versus 11.4%, respectively) as well as a higher 
adjusted hazard ratio (adjusted hazard ratio, 1.13 [95% CI, 1.00–1.27]; P=0.047). Patients with PAD had higher all-
cause mortality (adjusted hazard ratio 1.38 [95% CI, 1.20–1.60]; P<0.001) and more frequent LEA (adjusted hazard 
ratio 5.48 [95% CI, 4.16–7.22]; P<0.001). Patients treated with exenatide or placebo had similar rates of MACE and 
LEA, regardless of PAD status.
CONCLUSIONS: EXSCEL participants with PAD had higher rates of all-cause mortality and LEA compared with those without 
PAD. There were no differences in MACE or LEA rates with exenatide versus placebo.
VISUAL OVERVIEW: A visual overview is available for this article.
CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT01144338.
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Large randomized controlled trials in patients with diabetes mellitus (DM) have identified agents that confer cardiovascular benefits, but data for their 
effect on patients with peripheral artery disease (PAD) 
remain limited. Lower-extremity PAD affects ≈8.5 mil-
lion Americans over the age of 40 years and 202 mil-
lion people worldwide; many of these patients also have 
DM.1 Lower rates of major adverse cardiovascular events 
(MACE; cardiovascular mortality, nonfatal myocardial 
infarction (MI), and nonfatal stroke) were seen with 3 
GLP-1 (glucagon-like peptide-1) receptor agonists—
liraglutide, semaglutide, and albiglutide—in the LEADER 
trial (Liraglutide Effect and Action in Diabetes: Evalua-
tion of Cardiovascular Outcome Results), SUSTAIN-6 
(Trial to Evaluate Cardiovascular and Other Long-Term 
Outcomes With Semaglutide in Subjects With Type 2 
Diabetes), and Harmony Outcomes trial, respectively.2–4 
Although lixenatide and exenatide did not reduce MACE 
compared to placebo, pooled data from major random-
ized controlled trials studying GLP-1 receptor agonists 
demonstrated a 10% relative risk reduction in MACE 
with this class of agents (hazard ratio [HR] 0.90 [95% CI, 
0.82–0.99]; P=0.03).5–7 Additionally, 2 SGLT2 (sodium-
glucose cotransporter-2) inhibitors, canagliflozin, and 
empagliflozin, both reduced rates of MACE.8,9 However, 
canagliflozin led to a near doubling of lower-extremity 
amputation (LEA) rates when compared with placebo 
(HR, 1.97 [95% CI, 1.41–2.75]), with a majority of ampu-
tations occurring at the level of the toe or metatarsal.8 
To offer safe and effective medications to patients, it is 
important to study how these new agents affect patients 
with concurrent PAD and DM.
In this analysis of the Exenatide Study of Cardiovas-
cular Event Lowering trial (EXSCEL), we aimed to (1) 
describe differences in baseline clinical characteristics 
and cardiovascular risk factors in patients with and with-
out PAD; (2) examine the association between PAD and 
cardiovascular and lower-limb events; and (3) assess 
the effect of exenatide on cardiovascular and lower-limb 
adverse events in the PAD population.
METHODS
The data that support the findings of this study are available from 
the corresponding author upon reasonable request. EXSCEL 
was a double-blind, randomized controlled trial that studied 
the cardiovascular effects of adding once-weekly exenatide to 
usual care by randomizing 14 752 patients with type 2 DM to 
receive subcutaneous injection of either 2 mg of exenatide or 
matched placebo. Patients were followed for an average of 3.2 
years. The study design and rationale have been described.10 
The trial’s primary composite end point of cardiovascular death, 
nonfatal MI, and nonfatal stroke occurred in 11.4% of patients 
in the exenatide group and 12.2% of patients in the placebo 
group (HR, 0.91 [95% CI, 0.83–1.00]).7
Adults with type 2 DM, defined as glycated hemoglobin 
level of 6.5% to 10%, were eligible to enroll in the trial, and 
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WHAT IS KNOWN
• Large randomized controlled trials have identified
various GLP-1 (glucagon-like peptide-1) agonists
and SGLT2 (sodium-glucose cotransporter-2)
inhibitors that improve glycemic control, and
many are associated with a reduction in major
adverse cardiovascular events rates, but there
are concerns for some off-target effects, such
as canagliflozin’s association with higher rates of
lower-extremity amputations.
• EXSCEL (Exenatide Study of Cardiovascular Event
Lowering) studied the cardiovascular effects of
adding once a week exenatide to usual care in
diabetic patients and showed that the primary
end point of major adverse cardiovascular event
occurred in 11.4% of patients in the exenatide
group and 12.2% of patients in the placebo group
(hazard ratio, 0.91 [95% CI 0.83–1.00]).
WHAT THE STUDY ADDS
• Describes the baseline characteristics and cardio-
vascular risk factors for EXSCEL participants with
and without peripheral artery disease (PAD) and
shows that patients with PAD were less likely to be
on optimal medical therapy for secondary preven-
tion of cardiovascular disease.
• Describes the association of PAD with major
adverse cardiovascular events, all-cause mortality,
and lower-limb events.
• Examines the treatment effect of exenatide versus
placebo by PAD status on major adverse cardio-
vascular events, all-cause death, and lower-limb
events, and shows that exenatide was not associ-
ated with lower-extremity amputations in diabetic
patients with or without PAD.
73% of enrolled patients had previous cardiovascular disease 
defined as coronary artery disease, ischemic cerebrovascular 
disease, or atherosclerotic PAD. PAD was defined as includ-
ing prior nontraumatic amputation due to history of vascular 
disease, current symptoms of intermittent claudication, confir-
mation by an ankle-brachial index <0.90, or history of surgical 
or percutaneous lower-extremity revascularization procedure.
Key exclusion criteria comprised the following: >2 episodes 
of severe hypoglycemia requiring third-party assistance in the 
preceding year, end-stage renal disease, or an estimated glo-
merular filtration rate <30 mL/(min·1.73 m2) of body surface 
area, previous treatment with a GLP-1 receptor agonist, per-
sonal or family history of medullary thyroid carcinoma or mul-
tiple endocrine neoplasia type 2, and a baseline calcitonin level 
>40 ng/L. The trial was designed and overseen by a steer-
ing committee, and an independent data and safety monitor-
ing committee performed regular safety surveillance. Patients
were monitored for adverse events over the course of the trial
and a 90-day post-trial follow-up period. The site investigator
collected information on adverse events, including amputa-
tions, and captured them on the case report form. All patients
provided written informed consent. Institutional review board
approval was required at all participating institutions.
Outcomes
The primary efficacy outcome was the first occurrence of death 
from cardiovascular causes, nonfatal MI, or nonfatal stroke. 
Secondary efficacy outcomes were all-cause mortality, the indi-
vidual components of the primary outcome, and hospitalizations 
for acute coronary syndrome or heart failure. An independent 
clinical events classification committee, whose members were 
unaware of group assignments, adjudicated the primary and 
secondary efficacy outcomes. Additionally, postrandomization 
data for prespecified events of clinical interest were collected 
on specific clinical events pages. Lower-extremity end points, 
including the first occurrence of nontraumatic LEA, gangrene, 
and endovascular or surgical lower-extremity revascularization 
were ascertained at each visit by EXSCEL investigators, but 
these events were not adjudicated.
Statistical Analysis
This study is a post hoc subgroup analysis of the EXSCEL trial. 
Cox hazards regression models were used to examine the asso-
ciation between PAD and efficacy and safety outcomes, spe-
cifically cardiovascular and lower-limb events, and to assess the 
effect of exenatide as compared to placebo on cardiovascular 
and lower-limb events in the subgroup of patients with PAD.
For each outcome of interest, we used proportional hazards 
models to estimate the unadjusted HR comparing patients with 
a history of a PAD event at baseline versus patients who did not 
have a history of PAD. To estimate adjusted HRs, the following 
adjustment covariates (all significant at the level of P<0.05 in 
univariate analysis) were added to the models: age, sex, race, 
DM duration, glycated hemoglobin group, smoking status, and 
prior cardiovascular event at baseline, angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker, aspirin, β-
blocker, clopidogrel, other antiplatelet agents, and statin. These 
intrinsic patient-level variables were selected based off previ-
ously published risk models and thought to be independently 
associated with outcomes.11
Additionally, because 73% of participants in the original trial 
had established prior cardiovascular disease, we repeated the 
above analyses comparing subjects with PAD to those without 
PAD but with prior cardiovascular events.
To assess whether there was a differential effect of exena-
tide on each outcome by PAD status, models were constructed, 
including an interaction term between treatment and PAD sta-
tus. The P value of the test of the interaction term was used 
to determine whether an interactive effect existed. Additionally, 
unadjusted models were fitted within the baseline PAD status 
subgroups to estimate HRs comparing exenatide versus pla-
cebo. We repeated this analysis in all subjects with prior car-
diovascular disease to detect differences from the overall trial 
population. The Kaplan-Meier method was used to calculate 
event rates. Analyses were conducted using SAS software ver-
sion 9.4 (SAS Institute).
RESULTS
Patient Characteristics
The trial was designed such that ≈70% of enrolled 
patients would have had previous cardiovascular events, 
including a manifestation of coronary artery disease, 
ischemic cerebrovascular disease, or PAD. Of the 14 752 
patients enrolled in EXSCEL, 2800 (18.9%) had docu-
mented PAD. Of these, 345 had a prior endovascular 
or surgical revascularization procedure, and 546 had a 
nontraumatic amputation at the time of randomization. 
Baseline patient demographics and clinical characteris-
tics by the presence or absence of PAD are shown in 
Table 1. Patients with PAD were more likely to be black 
(10.6% versus 4.9%), had lower incidence of coronary 
artery disease (35.8% versus 56.8%), and were less 
likely to have had a prior MI (20% versus 34.5%) when 
compared with patients without PAD. Patients with PAD 
were more likely to be on insulin (54.8% versus 44.4%) 
and less likely to be on a statin (65.8% versus 75.3%), 
a β-blocker (45.4% versus 58.1%), an angiotensin-con-
verting enzyme inhibitor (45.2% versus 49.5%), or aspi-
rin (57.3% versus 65.0%), when compared with those 
without PAD. Of the 11 951 participants without PAD, 
there were 8045 (67%) who also had previous cardio-
vascular disease (as defined by coronary artery disease, 
MI, or cerebrovascular disease).
Clinical Outcomes (MACE and Limb Outcomes)
MACE occurred more frequently in patients with PAD 
compared with those without (13.6% versus 11.4%, 
respectively; unadjusted HR, 1.36 [95% CI, 1.21–1.52]; 
P<0.001; Table 2). This difference persisted after 
adjustment for patient characteristics and medications 
(adjusted hazard ratio [HRadj], 1.13 [95% CI, 1.00–1.27]; 
P=0.047). Patients with PAD did have higher adjusted 
rates of cardiovascular death when compared with 
patients without PAD (6.5% versus 4.5%; HRadj, 1.34 
[95% CI, 1.14–1.62]; P=0.001). All-cause mortality was 
higher in patients with PAD (10.0%) when compared 
with patients without PAD (6.8%; HRadj, 1.38 [95% CI, 
1.20–1.60]; P<0.001). Additionally, rates of first occur-
rence of fatal or nonfatal stroke were higher in patients 
with PAD (3.5%) when compared with patients without 
PAD (2.6%; HRadj, 1.29 [95% CI, 1.01–1.65]; P=0.044). 
When compared with patients without PAD, patients with 
PAD had higher unadjusted and adjusted rates of non-
traumatic amputations, gangrene, endovascular revascu-
larization, and surgical revascularization (Table 2).
MACE occurred at a rate of 13.6% in patients with 
PAD and 14.4% in those without PAD but with previous 
cardiovascular disease (HRadj, 1.12 [95% CI, 0.99–1.27]; 
P=0.062), changing to nonsignificance largely due to a 
reduction in population. After adjustment, there were no 
significant differences in all other outcomes, including 
all-cause mortality and lower-limb events, between the 
population with previous cardiovascular disease com-
pared with the overall population.
Treatment Effects of Exenatide
There was no significant difference in MACE in patients 
with PAD who received Exenatide or placebo (exena-
tide 12.8% versus placebo 14.5%; HR, 0.85 [95% CI, 
0.69–1.04]) and in those without PAD (exenatide 11.1% 
Table 1. Baseline Demographics and Patient Characteristics by History of PAD
PAD; N=2800 No PAD; N=11 951 All Participants; N=14 751
Age, y 62.4 (9.1) 61.8 (9.5) 61.9 (9.4)
Female sex (%) 40.7 37.3 38.0
Race
 White 2108/2798 (75.3) 9066/11 948 (75.9) 11 174/14 746 (75.8)
 Black 297/2798 (10.6) 581/11 948 (4.9) 878/14 746 (6.0)
 Asian 136/2798 (4.9) 1316/11 948 (11.0) 1452/14 746 (9.8)
 Hispanic 244/2798 (8.7) 890/11 948 (7.4) 1134/14 746 (7.7)
Body mass index, kg/m2 31.8 (5.9) 32.9 (6.5) 32.7 (6.4)
Duration of DM, y 13.9 (8.7) 12.9 (8.2) 13.1 (8.3)
HbA1c, % 8.2 (1.0) 8.1 (1.0) 8.1 (1.0)
eGFR, mL/min/1.73m2 75.5 (23.8) 79.0 (24.2) 78.4 (24.1)
Cigarette smoking status
 Current 380/2800 (13.6) 1341/11 944 (11.2) 1721/14 744 (11.7)
 Never 1225/2800 (43.8) 6008/11 944 (50.3) 7233/14 744 (49.1)
Prior history
Coronary artery disease 1001/2800 (35.8) 6792/11 951 (56.8) 7793/14 751 (52.8)
Cerebrovascular disease 459/2800 (16.4) 2050/11 950 (17.2) 2509/14 750 (17.0)
Prior myocardial infarction 559/2800 (20.0) 4120/11 951 (34.5) 4679/14 751 (31.7)
Antihyperglycemic agents
 Biguanides 2018/2800 (72.1) 9276/11 951 (77.6) 11 294/14 751 (76.6)
 Sulfonylurea 985/2800 (35.2) 4415/11 951 (36.9) 5400/14 751 (36.6)
 Thiazolidinedione 74/2800 (2.6) 504/11 951 (4.2) 578/14 751 (3.9)
 Insulin 1533/2800 (54.8) 5303/11 951 (44.4) 6836/14 751 (46.3)
DPP-4 inhibitors 303/2800 (10.8) 1900/11 951 (15.9) 2203/14 751 (14.9)
SGLT2 inhibitors 19/1869 (1.0) 58/6671 (0.9) 77/8540 (0.9)
Antihypertensive, antianginal, and other cardiovascular medications
ACE inhibitor 1266/2800 (45.2) 5915/11 951 (49.5) 7181/14 751 (48.7)
Angiotensin receptor blocker 879/2800 (31.4) 3727/11 951 (31.2) 4606/14 751 (31.2)
β-blocker 1270/2800 (45.4) 6940/11 951 (58.1) 8210/14 751 (55.7)
 Aspirin 1605/2800 (57.3) 7774/11 951 (65.0) 9379/14 751 (63.6)
 Clopidogrel/ticlopidine 492/2800 (17.6) 2032/11 951 (17.0) 2524/14 751 (17.1)
Lipid-lowering medication 1951/2800 (69.7) 9418/11 951 (78.8) 11 369/14 751 (77.1)
 Statin 1843/2800 (65.8) 9001/11 951 (75.3) 10 844/14 751 (73.5)
Values shown are mean (SD) or n/N (%), except where indicated otherwise. ACE indicates angiotensin-converting enzyme; DM, diabetes 
mellitus; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; PAD, peripheral artery disease; 
and SGLT2, sodium-glucose cotransporter-2.
versus placebo 11.7%; HR, 0.94 [95% CI, 0.84–1.04] 
interaction P=0.42; Table 3 and Figure 1). There was no 
treatment interaction associated with exenatide for the 
individual components of MACE, regardless of PAD sta-
tus (all P>0.05).
Finally, there was no differential treatment effect 
on rates of lower-limb composite events, nontraumatic 
amputations, gangrene, and endovascular/surgical revas-
cularization procedures in all participants (Figure 2). Spe-
cifically, treatment with exenatide or placebo had similar 
rates of nontraumatic amputations in those with PAD 
(5.0% in exenatide versus 4.9% in placebo; HR, 0.99 
[95% CI, 0.71–1.38]) and in those without PAD (0.9% 
in exenatide versus 0.9% in placebo; HR, 0.96 [95% CI, 
0.66–1.41] interaction P=0.92).
Lastly, the treatment effects of exenatide based on 
PAD status in participants with prior cardiovascular dis-
ease mirrored those of the overall population (see Table 4). 
There was also no differential treatment effect of exena-
tide in participants with prior cardiovascular disease.
DISCUSSION
This analysis of patients with PAD in EXSCEL has 4 key 
findings. First, PAD was included as a risk enrichment 
factor for the overall trial, but, surprisingly, patients with 
PAD were treated less aggressively for cardiovascular 
risk reduction with aspirin, statin, angiotensin-converting 
enzyme inhibitors, and β-blockers. Second, patients with 
PAD had higher unadjusted and adjusted rates of MACE 
and LEA when compared with patients without PAD. 
Third, there was no treatment interaction based on PAD 
status for MACE, key secondary end points, and lower-
limb events. Fourth, exenatide was not associated with 
LEA in patients with DM with and without baseline PAD.
PAD is up to 4×more frequent in patients with DM 
than the general population.12 The UK Prospective Dia-
betes Study showed that PAD prevalence increases with 
DM duration.13 Additionally, the degree of glycemic con-
trol is an independent risk factor for PAD; with every 1% 
increase in glycated hemoglobin, there is a 28% greater 
risk of development of PAD.13 Moreover, patients with 
DM and PAD were 5× more likely to have an amputation, 
had higher rates of cerebrovascular and cardiovascular 
disease, and had higher rates of cardiovascular and all-
cause mortality than nondiabetic patients with PAD.14,15 
Hence, it is imperative to thoroughly study novel antidia-
betic agents to prevent adverse limb outcomes in this 
inherently sick population.
Although many randomized controlled trials have 
been designed to determine the cardiovascular safety 
and efficacy of new antidiabetic agents, few trials before 
the CANVAS (Canagliflozin Cardiovascular Assessment) 
investigated LEA risks in detail.8 For instance, trials com-
paring dipeptidyl peptidase-4 inhibitors with placebo dem-
onstrated similar rates of MACE with either intervention 
in patients with DM, but no information was reported on 
adverse limb events.16–18 Similarly, some GLP-1 receptor 
Table 2. Association Between Baseline PAD and Outcomes
Outcomes
PAD No PAD Unadjusted Model Adjusted Model*
P ValueN=2800 N=11 951 HR (95% CI) P Value HR (95% CI)
Primary end point
 MACE 382 (13.6%) 1362 (11.4%) 1.36 (1.21–1.52) <0.001 1.13 (1.00–1.27) 0.047
Cardiovascular death 182 (6.5%) 541 (4.5%) 1.70 (1.44–2.02) <0.001 1.36 (1.14–1.62) 0.001
Nonfatal MI 184 (6.6%) 762 (6.4%) 1.16 (0.98–1.36) 0.077 0.95 (0.80–1.12) 0.522
Nonfatal stroke 86 (3.1%) 276 (2.3%) 1.50 (1.18–1.91) 0.001 1.28 (0.98–1.66) 0.066
Secondary end points
All-cause death 280 (10.0%) 811 (6.8%) 1.77 (1.55–2.03) <0.001 1.38 (1.20–1.60) <0.001
First occurrence of nonfatal or fatal MI 195 (7.0%) 781 (6.5%) 1.20 (1.02–1.40) 0.026 0.98 (0.83–1.15) 0.793
First occurrence of nonfatal or fatal stroke 97 (3.5%) 308 (2.6%) 1.51 (1.20–1.90) <0.001 1.29 (1.01–1.65) 0.044
Hospitalization for ACS 217 (7.8%) 955 (8.0%) 1.07 (0.92–1.24) 0.363 0.89 (0.76–1.03) 0.122
Hospitalization for heart failure 102 (3.6%) 348 (2.9%) 1.44 (1.15–1.80) 0.001 1.16 (0.92–1.46) 0.219
Limb events
Lower-limb composite event 290 (10.4%) 233 (2.0%) 6.14 (5.17–7.31) <0.001 5.53 (4.58–6.66) <0.001
Amputation (nontraumatic) 139 (5.0%) 108 (0.9%) 6.12 (4.75–7.87) <0.001 5.48 (4.16–7.22) <0.001
 Gangrene 96 (3.4%) 71 (0.6%) 6.44 (4.73–8.76) <0.001 6.03 (4.29–8.48) <0.001
Lower-extremity endovascular revascularization 126 (4.5%) 92 (0.8%) 6.69 (5.10–8.76) <0.001 5.27 (3.96–7.00) <0.001
Lower-extremity surgical revascularization 69 (2.5%) 36 (0.3%) 9.19 (6.12–13.80) <0.001 8.35 (5.44–12.82) <0.001
Values shown are n (%), except where indicated otherwise. ACE indicates angiotensin-converting enzyme; ACS, acute coronary syndrome; HR, hazard ratio; MACE, 
major adverse cardiac event; MI, myocardial infarction; and PAD, peripheral artery disease.
*Adjusted model includes PAD status, age, sex, race, diabetes mellitus duration, hemoglobin A1c status, smoking status, prior cardiovascular event, ACE inhibitor or
angiotensin receptor blocker, aspirin, β-blocker, clopidogrel, other antiplatelet agents, statin.
agonists (liraglutide, semaglutide, albiglutide) have been 
shown to have cardiovascular benefits, whereas others 
agents (lixisenatide and exenatide) demonstrated non-
inferiority on cardiovascular end points when compared 
with placebo.2–4,6,7 Nonetheless, effects of these agents 
on lower-extremity PAD were not fully examined. A recent 
post hoc analysis of LEADER showed that patients with 
DM treated with liraglutide had similar rates of developing 












N=1400 HR (95% CI)
Primary end point
 MACE 660 (11.1%) 702 (11.7%) 0.94 (0.84–1.04) 179 (12.8%) 203 (14.5%) 0.85 (0.69–1.04) 0.417
Cardiovascular death 256 (4.3%) 285 (4.8%) 0.90 (0.76–1.07) 84 (6.0%) 98 (7.0%) 0.83 (0.62–1.11) 0.66
Nonfatal MI 378 (6.4%) 384 (6.4%) 0.99 (0.86–1.14) 88 (6.3%) 96 (6.9%) 0.89 (0.66–1.19) 0.522
Nonfatal stroke 124 (2.1%) 152 (2.5%) 0.81 (0.64–1.03) 45 (3.2%) 41 (2.9%) 1.06 (0.69–1.61) 0.271
Secondary end points
All-cause death 383 (6.4%) 428 (7.1%) 0.90 (0.78–1.03) 124 (8.9%) 156 (11.1%) 0.77 (0.61–0.98) 0.288
First occurrence of nonfatal or fatal MI 388 (6.5%) 393 (6.6%) 0.99 (0.86–1.14) 95 (6.8%) 100 (7.1%) 0.92 (0.69–1.22) 0.65
First occurrence of nonfatal or fatal stroke 138 (2.3%) 170 (2.8%) 0.81 (0.65–1.01) 49 (3.5%) 48 (3.4%) 0.98 (0.66–1.47) 0.38
Hospitalization for ACS 495 (8.3%) 460 (7.7%) 1.08 (0.95–1.23) 107 (7.6%) 110 (7.9%) 0.95 (0.72–1.23) 0.369
Hospitalization for heart failure 178 (3.0%) 170 (2.8%) 1.05 (0.85–1.29) 41 (2.9%) 61 (4.4%) 0.65 (0.44–0.96) 0.035
Limb events
Lower-limb composite event 114 (1.9%) 119 (2.0%) 0.96 (0.74–1.24) 134 (9.6%) 156 (11.1%) 0.83 (0.66–1.04) 0.4
Amputation (nontraumatic) 53 (0.9%) 55 (0.9%) 0.96 (0.66–1.41) 70 (5.0%) 69 (4.9%) 0.99 (0.71–1.38) 0.923
 Gangrene 33 (0.6%) 38 (0.6%) 0.87 (0.55–1.38) 44 (3.1%) 52 (3.7%) 0.83 (0.55–1.23) 0.863
 Lower-extremity endovascular 
revascularization
48 (0.8%) 44 (0.7%) 1.09 (0.72–1.64) 51 (3.6%) 75 (5.4%) 0.65 (0.46–0.93) 0.062
Lower-extremity surgical revascularization 13 (0.2%) 23 (0.4%) 0.57 (0.29–1.11) 37 (2.6%) 32 (2.3%) 1.11 (0.69–1.78) 0.105
Values shown are n (%), except where indicated otherwise. ACS indicates acute coronary syndrome; HR, hazard ratio; MACE, major adverse cardiac event; MI 
myocardial infarction; and PAD, peripheral artery disease.
Figure 1. Kaplan-Meier curves for time to major adverse cardiac event composite event by treatment and baseline peripheral 
artery disease (PAD) status.
diabetic foot ulcers as those receiving placebo (3.8% with 
liraglutide versus 4.1% with placebo; HR, 0.90 [95% CI, 
0.75–1.13]) and lower rates of diabetic foot ulcer-related 
amputations (0.9% with liraglutide versus 1.4% with pla-
cebo; HR, 0.65 [95% CI, 0.45–0.95]).19 However, a prior 
diagnosis of PAD was not reported, and due to meth-
ods of data collection, only amputations associated with 
known diabetic foot ulcers were analyzed.
The SGLT2 inhibitor canagliflozin was found to 
decrease MACE in patients with DM; however, it was asso-
ciated with a near 2-fold increase in LEAs as reported in 
CANVAS and CANVAS-Renal studies.8 The pathophysi-
ologic mechanism to explain the increased LEAs remains 
unknown, as does whether the class of SGLT2 inhibitors 
is associated with amputations. A post hoc analysis of 
the EMPA-REG OUTCOME (BI 10773 [Empagliflozin] 
Cardiovascular Outcome Event Trial in Type 2 Diabetes 
Mellitus Patients), where lower-limb amputations were 
manually identified from searches of severe adverse 
events narratives, reported that empagliflozin and pla-
cebo had similar rates of LEAs (HR, 1.00 [95% CI, 0.70–
1.44]).20 As this study preceded CANVAS, there was no 
concern for amputation, and it was not a listed adverse 
event on the case report form. In contrast, a large retro-
spective cohort study of commercially insured patients 
found that new use of SGLT2 inhibitors was associated 
with a statistically significant increased risk of LEA com-
pared with use of metformin, sulfonylureas, or thiazoli-
dinediones (HR, 2.12 [95% CI, 1.19–3.77]). Among this 
SGLT2 inhibitor cohort, 70% were taking canagliflozin, 
with the remainder taking dapagliflozin or empagliflozin.21 
Lastly, the DECLARE-TIMI-58 trial (Dapagliflozin Effect 
on Cardiovascular Events–Thrombolysis in Myocardial 
Infarction 58) showed no difference in rates of ampu-
tation between patients treated with dapagliflozin or 
placebo (HR, 1.09 [95% CI, 0.84–1.40]).22 Of note, how-
ever, only 6% of enrolled patients had PAD.
This analysis from EXSCEL included a large cohort 
of patients with PAD with DM and directly compared 
the clinical characteristics, rates of MACE and LEA, and 
treatment effect of the GLP-1 receptor agonist exena-
tide according to PAD status. Our study provides evi-
dence that exenatide is not associated with LEA and can 
be safely used in patients with DM with and without PAD 
who are inherently at higher risk for LEA.
Limitations
This was a post hoc analysis of the EXSCEL trial, which 
was powered to study MACE and not LEA. There were 
differences between the PAD and no PAD groups based 
on inclusion criteria (eg, 70% of patients had established 
cardiovascular disease, and since PAD counted as an 
inclusion criterion, those patients without baseline PAD 
were, by definition, more likely to have other forms of car-
diovascular disease at study entry). Additionally, although 
we used multivariable models to attempt to adjust for 
known confounders between patients with and without 
PAD, we were not able to control for unknown con-
founders. Moreover, although site investigators identified 
Figure 2. Kaplan-Meier curves for time to lower-limb composite event by treatment and baseline peripheral artery disease 
(PAD) status.
patients with PAD by both objective and subjective mea-
sures, the severity of PAD, composition of PAD subset, 
and exact ankle-brachial index values were not captured 
on the case report forms. Additionally, although gangrene 
was differentiated from amputation, no information was 
available for diabetic foot ulcers, and thus, we cannot 
account for amputations that were a result of diabetic 
foot ulcers. Lastly, a major limitation of the EXSCEL trial 
is the high rate of premature discontinuation (≈40%) 
of treatment assignment, which was primarily driven by 
patient decision.
Conclusions
This post hoc analysis of the EXSCEL trial studying 
patients with DM and PAD showed that those with PAD 
were less likely to be on optimal medical therapy for sec-
ondary prevention of cardiovascular disease. Patients 
with PAD had similar adjusted rates of MACE when com-
pared with patients without PAD, although patients with 
PAD had higher rates of cardiovascular and all-cause 
mortality, and higher adverse lower-limb events, including 
LEA and limb revascularization. Lastly, exenatide was not 
associated with LEA in patients with or without PAD and 
was associated with lower all-cause mortality in patients 
with DM and PAD.
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N=1369 HR (95% CI)
Primary end point
 MACE 544 (13.5%) 589 (14.7%) 0.91 (0.81–1.02) 178 (13.0%) 197 (14.4%) 0.88 (0.72–1.08) 0.78
Cardiovascular death 213 (5.3%) 233 (5.8%) 0.91 (0.76–1.10) 84 (6.1%) 97 (7.1%) 0.85 (0.64–1.14) 0.697
Nonfatal MI 319 (7.9%) 337 (8.4%) 0.94 (0.81–1.09) 88 (6.4%) 93 (6.8%) 0.92 (0.69–1.23) 0.909
Nonfatal stroke 95 (2.4%) 122 (3.0%) 0.77 (0.59–1.01) 44 (3.2%) 39 (2.9%) 1.10 (0.72–1.69) 0.166
Secondary end points
All-cause death 315 (7.8%) 337 (8.4%) 0.93 (0.80–1.09) 121 (8.9%) 154 (11.3%) 0.77 (0.61–0.98) 0.192
First occurrence of nonfatal or fatal MI 329 (8.2%) 343 (8.5%) 0.95 (0.82–1.11) 95 (7.0%) 97 (7.1%) 0.95 (0.72–1.26) 0.991
First occurrence of nonfatal or fatal stroke 107 (2.7%) 139 (3.5%) 0.76 (0.59–0.98) 48 (3.5%) 46 (3.4%) 1.02 (0.68–1.53) 0.229
Hospitalization for ACS 424 (10.5%) 405 (10.1%) 1.04 (0.91–1.20) 107 (7.8%) 107 (7.8%) 0.98 (0.75–1.28) 0.672
Hospitalization for heart failure 153 (3.8%) 141 (3.5%) 1.08 (0.86–1.35) 41 (3.0%) 60 (4.4%) 0.66 (0.44–0.98) 0.036
Limb events
Lower-limb composite event 90 (2.2%) 100 (2.5%) 0.89 (0.67–1.19) 128 (9.4%) 156 (11.4%) 0.79 (0.63–1.00) 0.521
Amputation (nontraumatic) 39 (1.0%) 47 (1.2%) 0.82 (0.54–1.26) 66 (4.8%) 69 (5.0%) 0.94 (0.67–1.31) 0.644
 Gangrene 26 (0.7%) 30 (0.8%) 0.86 (0.51–1.46) 41 (3.0%) 52 (3.8%) 0.77 (0.51–1.16) 0.744
 Lower-extremity endovascular 
revascularization
41 (1.0%) 41 (1.0%) 0.99 (0.64–1.53) 49 (3.6%) 75 (5.5%) 0.63 (0.44–0.90) 0.111
Lower-extremity surgical revascularization 11 (0.3%) 19 (0.5%) 0.57 (0.27–1.21) 35 (2.6%) 32 (2.3%) 1.06 (0.66–1.71) 0.174
Values shown are n (%), except where indicated otherwise. ACS indicates acute coronary syndrome; HR, hazard ratio; MACE, major adverse cardiac event; MI 
myocardial infarction; and PAD, peripheral artery disease.
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